Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study ; volume:20 ; number:1 ; day:30 ; month:10 ; year:2018 ; pages:1-10 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (30.10.2018), 1-10, 12.2018
- Urheber
-
Roughley, Matthew
Sultan, Alyshah Abdul
Clarson, Lorna
Muller, Sara
Whittle, Rebecca
Belcher, John
Mallen, Christian D.
Roddy, Edward
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1746-1
- URN
-
urn:nbn:de:101:1-2018121822375554168834
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Roughley, Matthew
- Sultan, Alyshah Abdul
- Clarson, Lorna
- Muller, Sara
- Whittle, Rebecca
- Belcher, John
- Mallen, Christian D.
- Roddy, Edward
- SpringerLink (Online service)
Ähnliche Objekte (12)
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age